Suven Life Sciences, a biopharmaceutical company registered a rise in share price on Monday after its drug discovery portfolio which has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators resulted in the grant of one product patent from USA (8735423) and one product patent from South Korea (10-1410903).

The patents are corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030.

Shares of the company are trading at Rs 191, up Rs 8.4, or 4.60% at the Bombay Stock Exchange (BSE) on Monday at 11:04 a.m.

The scrip has touched an intra-day high of Rs 192.50 and low of Rs 178.90. The total volume of shares traded at the BSE is 266,468.